1. Home
  2. ARTL vs TCRT Comparison

ARTL vs TCRT Comparison

Compare ARTL & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • TCRT
  • Stock Information
  • Founded
  • ARTL 2011
  • TCRT 1998
  • Country
  • ARTL United States
  • TCRT United States
  • Employees
  • ARTL N/A
  • TCRT N/A
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • TCRT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARTL Health Care
  • TCRT Health Care
  • Exchange
  • ARTL Nasdaq
  • TCRT Nasdaq
  • Market Cap
  • ARTL 3.1M
  • TCRT 3.8M
  • IPO Year
  • ARTL N/A
  • TCRT N/A
  • Fundamental
  • Price
  • ARTL $1.05
  • TCRT $2.46
  • Analyst Decision
  • ARTL Strong Buy
  • TCRT
  • Analyst Count
  • ARTL 2
  • TCRT 0
  • Target Price
  • ARTL $5.50
  • TCRT N/A
  • AVG Volume (30 Days)
  • ARTL 47.0K
  • TCRT 16.5K
  • Earning Date
  • ARTL 05-13-2025
  • TCRT 05-15-2025
  • Dividend Yield
  • ARTL N/A
  • TCRT N/A
  • EPS Growth
  • ARTL N/A
  • TCRT N/A
  • EPS
  • ARTL N/A
  • TCRT N/A
  • Revenue
  • ARTL N/A
  • TCRT $11,000.00
  • Revenue This Year
  • ARTL N/A
  • TCRT $5,680,500.00
  • Revenue Next Year
  • ARTL N/A
  • TCRT N/A
  • P/E Ratio
  • ARTL N/A
  • TCRT N/A
  • Revenue Growth
  • ARTL N/A
  • TCRT 83.33
  • 52 Week Low
  • ARTL $0.82
  • TCRT $1.31
  • 52 Week High
  • ARTL $1.55
  • TCRT $11.50
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 58.54
  • TCRT 44.90
  • Support Level
  • ARTL $0.90
  • TCRT $2.50
  • Resistance Level
  • ARTL $1.02
  • TCRT $2.95
  • Average True Range (ATR)
  • ARTL 0.07
  • TCRT 0.16
  • MACD
  • ARTL 0.01
  • TCRT -0.05
  • Stochastic Oscillator
  • ARTL 62.18
  • TCRT 2.00

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.

Share on Social Networks: